Real World Clinical Experience from ENABLE, the First Phase Four Observational Study for Patients With Relapsing Multiple Sclerosis Initiating Ublituximab (P9-19.005)

Key Points

The study aims to assess the clinical experiences of patients with relapsing multiple sclerosis (MS) receiving ublituximab treatment.
Phase four observational study
Focus on patients initiating ublituximab therapy
Evaluation of treatment provided insights into patient outcomes and experiences with ublituximab therapy.

Answers are grounded in this paper and cite their sources.

Observational study evaluates treatment experiences in relapsing MS patients with ublituximab, indicating practical implications.

To evaluate the real-world clinical experience of patients with relapsing MS treated with ublituximab.

No takes yet. Share an insight, caveat, or question.

Hersh et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share